KF 58333
Latest Information Update: 26 Oct 2006
At a glance
- Originator Kyowa Hakko
- Class Antineoplastics; Oximes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic myeloid leukaemia